Novelties in Therapy of Chronic Heart Failure

Heart Fail Clin. 2021 Apr;17(2):255-262. doi: 10.1016/j.hfc.2021.01.006. Epub 2021 Feb 11.

Abstract

In recent decades, considerable advances have been made in the treatment of heart failure. The main target of heart failure therapy is the inhibition of the sympathetic nervous system and renin-angiotensin-aldosterone system. The angiotensin receptor blockers represent a breakthrough in the treatment of heart failure with a demonstrated effect on reduction of cardiovascular events. However, new perspectives derive from latest drugs developed for diabetes, iron deficiency, and hyperkalemia. New frontiers are also opened to the development of neurohormonal therapies, antagonists of inflammatory mediators, inotropic agents, and cell-based treatments.

Keywords: Chronic heart failure; Comorbidities; Neurohormonal antagonists; New therapies; Preserved ejection fraction; Reduced ejection fraction.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Humans
  • Mineralocorticoid Receptor Antagonists / therapeutic use*
  • Renin-Angiotensin System / physiology*

Substances

  • Angiotensin Receptor Antagonists
  • Angiotensin-Converting Enzyme Inhibitors
  • Mineralocorticoid Receptor Antagonists